Revenue grew 163% last year and is guided to roughly double again — with both flagship LOIs now actually shipping. Judge it on the ramp, not on this quarter's loss.
Two years of doubling. FY25 +163%, FY26 guided ~+100% — this is the number that defines the thesis.
This is the entire growth case in one picture: AmpliTech roughly doubled revenue in FY2025 (+163% to ~$25M) and guides to roughly double again in FY2026 ($50M+). That's not a story about a single order — it's a two-year ramp driven by the O-RAN 5G division crossing from development into commercial production. Critically, the guidance is reaffirmed, not aspirational hand-waving: management has tied it to current backlog and to LOIs that are already shipping (next section). A debt-free company compounding revenue at triple- then double-digit rates is a growth object — and growth objects are priced off the slope of that line, not off a trailing P&L.
AmpliTech's sales more than doubled last year and the company expects them to roughly double again this year. That kind of back-to-back doubling is the whole reason to look at it — and it's backed by real orders that have started shipping, not just promises.
From R&D to revenue. The flagship LOIs aren't pipeline anymore — they're shipping.
The reason the ramp is credible is that the O-RAN 5G division has crossed the hardest line for any hardware company: from qualification into commercial production. The proof is in what's actually moving:
| Catalyst | Status | Why it matters for growth |
|---|---|---|
| $100M LOI | Production shipments started Dec 2025 | The anchor — multi-year, multi-config O-RAN volume now converting to revenue |
| $40M LOI (N. American MNO) | Shipping resumed Q1 2026 · $20M+ already shipped | Concurrent production with the $100M LOI — manufacturing is execution-ready |
| Third LOI >$70M | Referenced · pipeline | The next leg — shows the funnel is deepening, not one-and-done |
| 64T64R O-RAN certification | Achieved (first US company) | The gate that lets carriers buy — now cleared |
| R&D expense | Falling as programs commercialize | Spend shifts from development to delivery — operating leverage ahead |
This is the key growth distinction. A year ago AMPG's LOIs were future promises; today the company says it is making concurrent production shipments under both the $100M and $40M LOIs simultaneously — which is the single most important growth signal a hardware micro-cap can give, because it proves the supply chain and manufacturing can actually deliver multi-million-dollar volume. The certification cleared the gate; the shipments prove the throughput. That's why FY26's ~100% guide is anchored, not hopeful.
The big orders everyone talked about last year have started actually shipping — both at the same time. For a small hardware company, proving you can manufacture and ship big orders simultaneously is the hardest and most important milestone. It's the difference between "we have a contract" and "we're delivering on it," and AmpliTech just crossed that line.
The growth is getting more profitable as it scales. 33%→48% gross margin, falling R&D — the leverage is starting.
| Metric (Q1 FY26) | Value | Growth read |
|---|---|---|
| Revenue | $5.35M · +48.6% YoY | accelerating; Q2 guided > Q1 |
| Gross profit | $2.57M · +116% YoY | growing 2.4x faster than revenue — leverage |
| Gross margin | 48.0% (was 33.0%) | mix shift to commercial terms |
| Mfg/engineering segment | $3.28M (was $0.99M) | 3.3x — the O-RAN production engine |
| R&D trend | Falling as programs commercialize | spend converting to deliverable revenue |
| Net loss | $(1.52)M · improved 17% | still a loss — the one growth caveat |
| Balance sheet | Debt-free · current ratio 4.25 | can fund the ramp |
The growth-quality tell is that gross profit grew 116% while revenue grew 49% — profit scaling more than twice as fast as the top line is exactly the operating-leverage signature you want to see in a company climbing its ramp. Margin went 33%→48% as early "foot-in-the-door" pricing gives way to commercial terms, and R&D is falling as programs move from development to delivery. The business still posts a net loss — that's the honest caveat — but the direction of every operating metric is converging toward profitability as volume scales. For a growth holder, the loss today matters less than the slope: revenue doubling, gross profit more than doubling, margin expanding, R&D falling.
As sales grow, profit is growing even faster — gross profit jumped 116% while revenue rose 49%. That's the sign of a business getting more efficient as it scales. It still loses money overall, but every trend line points toward profitability as the big orders ship in volume.
What could break the ramp. Timing and dilution — not demand.
▲ What's working for the ramp
- Two-year doubling: +163% FY25, ~+100% guided FY26 — reaffirmed, backlog-anchored.
- LOIs shipping concurrently: $100M + $40M in simultaneous production — throughput proven.
- Operating leverage starting: gross profit +116% on +49% revenue; R&D falling.
- Certified & first-mover: first US 64T64R O-RAN cert — the gate is cleared.
- Debt-free with a deep LOI funnel (incl. a third >$70M).
▼ What could stall it
- H2-weighted & lumpy: revenue back-loaded; LOI shipments can slip between quarters.
- Still loss-making: net loss $(1.52)M — profitability is a forward expectation, not a fact yet.
- Dilution funds the build: share count has risen materially; more rights/warrants outstanding.
- LOIs aren't firm POs: letters of intent convert in funded tranches — conversion pace is the variable.
- Supply-chain timing: management flagged logistics/geopolitical delays hitting Q1.
Notice the asymmetry: none of the real risks are demand risks. The ramp's threats are timing (lumpy, H2-weighted conversion) and funding (dilution), not "will anyone buy this." For a growth investor that's the better kind of risk — execution and cadence, which the company is now demonstrably managing (concurrent shipments), rather than a question of whether the market exists. The thing to watch each quarter is simply whether the H2 ramp shows up on schedule and whether margin keeps climbing toward the LOI-volume mix.
The dangers here aren't about whether customers want the product — they clearly do. They're about timing (orders arriving in uneven chunks, weighted to late in the year) and the company selling shares to fund growth. Those are normal growing-pains risks, not existential ones — the key is watching that the big second-half ramp actually lands on schedule.
Scored on the ramp. Growth trajectory: 8/10 · entry for a growth holder: 6.5/10.
Judged as a growth name — the lens you asked for — AMPG rates well on trajectory and acceptably on entry, with the loss and dilution as the honest drags.
| Dimension (growth lens) | Grade | Why |
|---|---|---|
| Revenue trajectory | A | +163% then ~+100% — back-to-back doubling, reaffirmed |
| Catalyst conversion | A− | Both flagship LOIs in concurrent production — throughput proven |
| Operating leverage | B+ | GP +116% on rev +49%; margin 33→48%; R&D falling |
| TAM / runway | B+ | O-RAN re-shoring + AI-RAN — real, policy-favored, multi-year |
| Profitability today | C− | Still a net loss — the main growth caveat |
| Funding quality | C | Dilution funds the ramp; debt-free but share count rising |
On the growth lens this is an 8/10 trajectory — a debt-free micro-cap doubling revenue two years running with its anchor contracts now shipping concurrently is a genuine ramp, not a story. The entry rates a 6.5: you're paying for that ramp while the company is still loss-making and diluting, so it's a real growth bet rather than a sure thing — but the conversion proof (simultaneous LOI shipments) de-risks it meaningfully versus the pure "positioning option" read. The number that governs it all: whether the H2-weighted ramp toward $50M lands, and whether gross margin keeps climbing as LOI volume mixes in.
As a growth stock, AmpliTech rates an 8 — doubling sales two years running with big orders now shipping. Buying it rates a 6.5, because it still loses money and sells shares to grow. It's a real growth bet with real momentum behind it; the thing to watch is whether the big second-half sales surge actually arrives.
John's read — growth lens. The ramp is real and shipping; price the slope, watch the H2 cadence.
- On a growth basis, this is more compelling than a static screen shows. +163% then a guided ~+100% — back-to-back doubling — with both flagship LOIs now in concurrent production is a genuine ramp. That's the lens that matters for a name like this, and on it AMPG is an 8/10 trajectory.
- The conversion proof is what changed my read. Last time I framed it as a positioning option. The new fact that moves it: the $100M and $40M LOIs are shipping simultaneously — proving manufacturing throughput, which is the hardest thing for a hardware micro-cap to demonstrate. That de-risks the ramp materially.
- Operating leverage is starting. Gross profit growing 116% on 49% revenue, margin 33→48%, R&D falling as programs commercialize. The loss is still there — the honest caveat — but every operating line is converging toward profit as volume scales.
- The risks are timing and dilution, not demand. Revenue is H2-weighted and lumpy, and dilution funds the build. Those are growing-pains risks, the kind a growth holder accepts — not an existential "does the market exist" problem.
- How I'd play it: a growth position sized for volatility, keyed to one question each quarter — does the H2 ramp toward $50M show up, and does margin keep climbing? If yes, the slope justifies the price. This is the growth-ramp read; pair it with the positioning artifact for the full picture on the moat.
Want the quarterly ramp-tracker — the H2 checkpoints that confirm or kill the $50M?
Join the Discord to find out! →AmpliTech FY2025 results 8-K (Jan 5, 2026 — ~$25M rev +163%, $50M+ FY26 reaffirm, $100M LOI shipments started Dec 2025, $40M LOI resuming Q1) · Q1 FY26 8-K, 10-Q & earnings release (May 13 — $5.35M +48.6%, GP +116%, 48% GM, R&D falling, $(1.52)M net loss, backlog >$20M, third LOI >$70M referenced) · FY25 conf-call/5G pipeline update (Mar 27 — $20M+ shipped under $40M LOI) · O-RAN 64T64R certification release (Jan 20) · TipRanks growth/timing coverage. Figures from SEC filings & company releases; growth-trajectory analysis, not a recommendation.